Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbon ion radiotherapy plus SHR-1210 in metastatic hepatocellular carcinoma
CTR20170910Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started Aug 2017; status: active.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20170910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170910.